New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
06:43 EDTGILD, RHHBY, MRK, ABBV, BMYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Several companies, including Roche (RHHBY) and Merck (MRK) have taken aggressive legal steps to claim that Gilead's (GILD) Sovaldi infringes upon their patents or contract rights and deserve a cut of the sales, reports the Wall Street Journal. Abbvi (ABBV), meanwhile, has obtained U.S. patents covering combinations of dozens of drugs to treat hepatitis-C as it develops a treatment of its own. Abbvie, Merck and Bristol-Myers Squibb (BMY) are also planning to bring their own regimens to market to compete with Gilead's. Reference Link
News For GILD;RHHBY;MRK;ABBV;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 23, 2014
10:54 EDTABBVStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
09:13 EDTABBVOn The Fly: Pre-market Movers
Subscribe for More Information
08:07 EDTGILDFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
08:03 EDTABBVAbbVie to present several oncology pipeline studies
AbbVie announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline will be presented at the upcoming 2014 European Society of Medical Oncology Annual Congress, September 26-30, in Madrid, Spain. Data being presented include results from a Phase 2 study evaluating the safety and efficacy of veliparib, or ABT-888, a poly polymerase inhibitor, in combination with two broad-acting chemotherapeutic medicines in patients with non-small cell lung cancer. Results from a Phase 1 study of ABT-414 in patients with newly diagnosed glioblastoma multiforme will also be presented during an oral presentation. Reference Link
07:33 EDTMRKOphthotech names Michael Atieh as EVP, Chief Financial and Business Officer
Ophthotech Corporation (OPHT) announced that Michael G. Atieh has been named EVP, Chief Financial and Business Officer and Treasurer effective September 30. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the company of his intention to retire effective September 30. Atieh spent the majority of his career in the pharmaceutical industry with Merck and Co (MRK), where he held various senior level positions over a 20 year period including Senior Vice President-Merck Medco Managed Care, Vice President-U.S. Human Health, Vice President-Public Affairs, Vice President-Government Relations, and Treasurer.
September 22, 2014
19:23 EDTRHHBYRoche management to meet with JPMorgan
Subscribe for More Information
13:53 EDTRHHBYRoche launches $5.75B bond to back InterMune acquisition, Reuters reports
Subscribe for More Information
09:15 EDTGILDIntercept recent weakness a buying opportunity, says Summer Street
Subscribe for More Information
07:21 EDTBMYEBD Group to hold a conference
Subscribe for More Information
06:51 EDTMRKMerck to host conference call
Subscribe for More Information
September 20, 2014
15:43 EDTRHHBYInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information
September 19, 2014
11:26 EDTGILDStocks with call strike movement; TSLA GILD
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
06:25 EDTGILDGilead granted marketing aurhotization from European Commission for Zydelig
Subscribe for More Information
06:11 EDTGILDGilead price target raised to $139 from $111 at Citigroup
Citigroup raised its price target for Gilead shares to $139 saying management looks "very optimistic" that FY15 hepatitis C treatment volumes could be up substantially over FY14 rates globally. Citi also expects recent buybacks to boost Q4 earnings substantially and that future stock buybacks will drive appreciation. The firm keeps a Buy rating on Gilead.
September 18, 2014
12:12 EDTGILDStocks with call strike movement; PIR GILD
Subscribe for More Information
11:15 EDTABBVRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
08:17 EDTGILDGilead trial failure not material, says FBR Capital
Subscribe for More Information
06:10 EDTABBVFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use